Carregant...
Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats
Despite the high prevalence of use of methamphetamine (METH), there is no FDA-approved pharmacological treatment available currently for METH addiction. The vesicular monoamine transporter (VMAT2) has been proposed as a novel target to treat METH abuse. GZ-793A, a lobelane analog and selective VMAT2...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3842023/ https://ncbi.nlm.nih.gov/pubmed/24075974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pbb.2013.09.006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|